Document Detail


Evaluation of WO2012003387, Gilead's ASK1 inhibitors.
MedLine Citation:
PMID:  22439661     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
A small number of novel N-(triazolylthiazol-2-yl) and N-(triazolylthienyl) benzamide and picolinamide derivatives are claimed. The compounds are ASK1 kinase inhibitors among which some have nanomolar potency and are potentially useful in the treatment of a diverse range of conditions. The claimed compounds define a pharmacophore, distinct from that described in the limited number of patent filings claiming ASK1 inhibitors.
Authors:
Peter Norman
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-23
Journal Detail:
Title:  Expert opinion on therapeutic patents     Volume:  -     ISSN:  1744-7674     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9516419     Medline TA:  Expert Opin Ther Pat     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Norman Consulting , 18 Pink Lane, Burnham, Bucks, SL1 8JW , UK peter.norman2@btinternet.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Germyl- and Germylene-Bridged Complexes of Rh/Ir and Subsequent Chemistry of a Bridging Germylene Gr...
Next Document:  Differential response of normal human epidermal keratinocytes and HaCaT cells to hydrogen peroxide-i...